A Unique Drug Distribution Process for Radium Ra 223 Dichloride Injection and Its Implication for Product Quality, Patient Privacy, and Delineation of Professional Responsibilities

On May 15, 2013, Bayer Healthcare Pharmaceuticals announced that it had received marketing approval for the therapeutic radioactive medication radium Ra 223 dichloride injection (Xofigo; Ra 223). The product acquisition and distribution process for hospital-based nuclear pharmacies and nuclear medic...

Full description

Saved in:
Bibliographic Details
Published in:The Annals of pharmacotherapy 2014-11, Vol.48 (11), p.1512-1514
Main Author: Dansereau, Raymond N.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Confidentiality
Humans
Injections
Medical sciences
Pharmacology. Drug treatments
Pharmacy Service, Hospital
Radioisotopes
Radiopharmaceuticals
Radium
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:On May 15, 2013, Bayer Healthcare Pharmaceuticals announced that it had received marketing approval for the therapeutic radioactive medication radium Ra 223 dichloride injection (Xofigo; Ra 223). The product acquisition and distribution process for hospital-based nuclear pharmacies and nuclear medicine services is unlike any other. The product is distributed as a low-risk compounded sterile preparation through a single compounding nuclear pharmacy located in Denver, Colorado, pursuant to a prescription. This model for drug distribution and delivery to the user institution has implications for product quality, patient privacy, and delineation of professional responsibilities.
ISSN:1060-0280
1542-6270
DOI:10.1177/1060028014545644